Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v3-FR Version v1-EN
Language French English
Date Updated 2017-10-31 2017-10-31
Drug Identification Number 02347113 02347113
Brand name NIASTASE RT NIASTASE RT
Common or Proper name Eptacog Alfa (activated) Eptacog Alfa (activated)
Company Name NOVO NORDISK CANADA INC NOVO NORDISK CANADA INC
Ingredients EPTACOG ALFA EPTACOG ALFA
Strength(s) 1MG 1MG
Dosage form(s) KIT POWDER FOR SOLUTION KIT POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size One vial of 1mg (50 KIU) per carton One vial of 1mg (50 KIU) per carton
ATC code B02BD B02BD
ATC description VITAMIN K AND OTHER HEMOSTATICS VITAMIN K AND OTHER HEMOSTATICS
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date 2017-10-27 2017-10-27
Actual discontinuation date 2017-10-27 2017-10-27
Remaining supply date 2017-10-27 2017-10-27
Discontinuation status Discontinued Discontinued
Discontinuation decision reversal no no
Information on remaining supply
Company comments The drug product is available as Niastase RT powder vial/pre-filled solvent syringe presentation The drug product is available as Niastase RT powder vial/pre-filled solvent syringe presentation
Health Canada comments